{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:52Z","timestamp":1791241672743,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T00:00:00Z","timestamp":1435536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00280-015-2813-9","type":"journal-article","created":{"date-parts":[[2015,6,28]],"date-time":"2015-06-28T06:48:01Z","timestamp":1435474081000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer"],"prefix":"10.1007","volume":"76","author":[{"given":"Ursula","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Obermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,29]]},"reference":[{"key":"2813_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics 2014. CA Cancer J Clin 64:9\u201329","journal-title":"CA Cancer J Clin"},{"key":"2813_CR2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419\u20131425","journal-title":"J Clin Oncol"},{"key":"2813_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136","journal-title":"N Engl J Med"},{"key":"2813_CR4","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine\/carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO OVAR, NCIC CTG and EORTC GCG. J Clin Oncol 24:4699\u20134706","journal-title":"J Clin Oncol"},{"key":"2813_CR5","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"2813_CR6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"JA Ledermann","year":"2012","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. NEJM 366:1382\u20131392","journal-title":"NEJM"},{"key":"2813_CR7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III study of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"2813_CR8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","volume":"280","author":"VM Richon","year":"2009","unstructured":"Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201\u2013210","journal-title":"Cancer Lett"},{"key":"2813_CR9","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","volume":"21","author":"N Takai","year":"2004","unstructured":"Takai N, Kawamata N, Gui D et al (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 21:2760\u20132770","journal-title":"Cancer"},{"key":"2813_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-6-183","volume":"6","author":"J Sonnemann","year":"2006","unstructured":"Sonnemann J, Gange J, Pilz S et al (2006) Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6:183","journal-title":"BMC Cancer"},{"key":"2813_CR11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2006.09.011","volume":"104","author":"AL Cooper","year":"2007","unstructured":"Cooper AL, Greenberg VL, Lancaster PS et al (2007) In vitro and in vivo histone deacetylase inhibitor activity with SAHA and paclitaxel in ovarian cancer. Gynecol Oncol 104:596\u2013601","journal-title":"Gynecol Oncol"},{"key":"2813_CR12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjc.6604557","volume":"99","author":"L Nolan","year":"2008","unstructured":"Nolan L, Johnson PWM, Ganesan A et al (2008) Will histone deacetylase inhibitors require combination with other agents to fulfill their therapeutic potential? Br J Cancer 99:689\u2013694","journal-title":"Br J Cancer"},{"key":"2813_CR13","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291\u20137300","journal-title":"Cancer Res"},{"key":"2813_CR14","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/1078-0432.CCR-07-2114","volume":"13","author":"VR Fantin","year":"2007","unstructured":"Fantin VR, Richon VM (2007) Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13:7237\u20137242","journal-title":"Clin Cancer Res"},{"key":"2813_CR15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","volume":"2","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors\u2014development of a new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Prac Oncol 2:150\u2013157","journal-title":"Nat Clin Prac Oncol"},{"key":"2813_CR16","first-page":"627","volume":"2004","author":"B Gabrielli","year":"1030","unstructured":"Gabrielli B, Warrener R, Burgess A et al (1030) Defining the chemotherapeutic targets of histone deacetylase inhibitors. Ann NY Acad Sci 2004:627\u2013635","journal-title":"Ann NY Acad Sci"},{"key":"2813_CR17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","volume":"109","author":"SC Modesitt","year":"2008","unstructured":"Modesitt SC, Sill M, Hoffman JS et al (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182\u2013186","journal-title":"Gynecol Oncol"},{"key":"2813_CR18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","volume":"46","author":"HJ Mackay","year":"2010","unstructured":"Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) tumors. Eur J Cancer 46:1573\u20131579","journal-title":"Eur J Cancer"},{"key":"2813_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck S et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2813_CR20","unstructured":"FDA package insert for gemcitabine for relapsed ovarian cancer. http:\/\/www.gemzar.com . Accessed 22 June 2015"},{"key":"2813_CR21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/IGC.0b013e31828566f1","volume":"23","author":"AA Mendevil","year":"2013","unstructured":"Mendevil AA, Micha JP, Brown JV, Rettenmaier MA, Abaid LN et al (2013) Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 23:533\u2013539","journal-title":"Int J Gynecol Cancer"},{"key":"2813_CR22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","volume":"28","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M et al (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non small cell lung cancer. J Clin Oncol 28:56\u201362","journal-title":"J Clin Oncol"},{"key":"2813_CR23","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"J Tredaniel","year":"2009","unstructured":"Tredaniel J, Descourt R, Moro-Sibilot D, Misset J, Gachard E et al (2009) Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer: a phase I dose escalation study. J Clin Oncol 27:15s (suppl; abstr 8049)","journal-title":"J Clin Oncol"},{"key":"2813_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","volume":"125","author":"DS Dizon","year":"2012","unstructured":"Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL et al (2012) A phase II of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:367\u2013371","journal-title":"Gynecol Oncol"},{"key":"2813_CR25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1023\/A:1011605008922","volume":"12","author":"A Bois du","year":"2001","unstructured":"du Bois A, Luck HJ, Pfisterer J et al (2001) Second line carboplatin and gemcitabine in platinum sensitive ovarian cancer\u2014a dose finding study by the Arbeitgemeinschaft Gynakologische (AGO) ovarian cancer study group. Ann Oncol 12:1115\u20131120","journal-title":"Ann Oncol"},{"key":"2813_CR26","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852\u2013861","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"2813_CR27","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 133:599\u2013606","DOI":"10.1016\/j.ygyno.2014.03.007"},{"key":"2813_CR28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1464-410X.2011.10533.x","volume":"109","author":"A Sato","year":"2011","unstructured":"Sato A, Asano T, Ito K, Sumitomo M, Asano T (2011) Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. Br J Urol 109:1258\u20131268","journal-title":"Br J Urol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2813-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2813-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:37Z","timestamp":1559023657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2813-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2813"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2813-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,29]]}}}